390 related articles for article (PubMed ID: 9652994)
21. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group.
Liberman UA; Weiss SR; Bröll J; Minne HW; Quan H; Bell NH; Rodriguez-Portales J; Downs RW; Dequeker J; Favus M
N Engl J Med; 1995 Nov; 333(22):1437-43. PubMed ID: 7477143
[TBL] [Abstract][Full Text] [Related]
22. A randomized trial comparing hormone replacement therapy (HRT) and HRT plus calcitriol in the treatment of postmenopausal osteoporosis with vertebral fractures: benefit of the combination on total body and hip density.
Gutteridge DH; Holzherr ML; Retallack RW; Price RI; Will RK; Dhaliwal SS; Faulkner DL; Stewart GO; Stuckey BG; Prince RL; Criddle RA; Drury PJ; Tran L; Bhagat CI; Kent GN; Jamrozik K
Calcif Tissue Int; 2003 Jul; 73(1):33-43. PubMed ID: 14506952
[TBL] [Abstract][Full Text] [Related]
23. Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis.
Chesnut CH; Skag A; Christiansen C; Recker R; Stakkestad JA; Hoiseth A; Felsenberg D; Huss H; Gilbride J; Schimmer RC; Delmas PD;
J Bone Miner Res; 2004 Aug; 19(8):1241-9. PubMed ID: 15231010
[TBL] [Abstract][Full Text] [Related]
24. The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis.
Meunier PJ; Roux C; Seeman E; Ortolani S; Badurski JE; Spector TD; Cannata J; Balogh A; Lemmel EM; Pors-Nielsen S; Rizzoli R; Genant HK; Reginster JY
N Engl J Med; 2004 Jan; 350(5):459-68. PubMed ID: 14749454
[TBL] [Abstract][Full Text] [Related]
25. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators.
Ettinger B; Black DM; Mitlak BH; Knickerbocker RK; Nickelsen T; Genant HK; Christiansen C; Delmas PD; Zanchetta JR; Stakkestad J; Glüer CC; Krueger K; Cohen FJ; Eckert S; Ensrud KE; Avioli LV; Lips P; Cummings SR
JAMA; 1999 Aug; 282(7):637-45. PubMed ID: 10517716
[TBL] [Abstract][Full Text] [Related]
26. Quantitative ultrasound and vertebral fracture in postmenopausal women. Fracture Intervention Trial Research Group.
Bauer DC; Glüer CC; Genant HK; Stone K
J Bone Miner Res; 1995 Mar; 10(3):353-8. PubMed ID: 7785455
[TBL] [Abstract][Full Text] [Related]
27. Effect of denosumab on trabecular bone score in postmenopausal women with osteoporosis.
McClung MR; Lippuner K; Brandi ML; Zanchetta JR; Bone HG; Chapurlat R; Hans D; Wang A; Zapalowski C; Libanati C
Osteoporos Int; 2017 Oct; 28(10):2967-2973. PubMed ID: 28748386
[TBL] [Abstract][Full Text] [Related]
28. A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study. PROOF Study Group.
Chesnut CH; Silverman S; Andriano K; Genant H; Gimona A; Harris S; Kiel D; LeBoff M; Maricic M; Miller P; Moniz C; Peacock M; Richardson P; Watts N; Baylink D
Am J Med; 2000 Sep; 109(4):267-76. PubMed ID: 10996576
[TBL] [Abstract][Full Text] [Related]
29. Bone mineral density at different sites and vertebral fractures in Serbian postmenopausal women.
Ilic Stojanovic O; Vuceljic M; Lazovic M; Gajic M; Radosavljevic N; Nikolic D; Andjic M; Spiroski D; Vujovic S
Climacteric; 2017 Feb; 20(1):37-43. PubMed ID: 27860483
[TBL] [Abstract][Full Text] [Related]
30. Increases in hip and spine bone mineral density are predictive for vertebral antifracture efficacy with ibandronate.
Miller PD; Delmas PD; Huss H; Patel KM; Schimmer RC; Adami S; Recker RR
Calcif Tissue Int; 2010 Oct; 87(4):305-13. PubMed ID: 20737140
[TBL] [Abstract][Full Text] [Related]
31. Superiority of a combined treatment of Alendronate and Alfacalcidol compared to the combination of Alendronate and plain vitamin D or Alfacalcidol alone in established postmenopausal or male osteoporosis (AAC-Trial).
Ringe JD; Farahmand P; Schacht E; Rozehnal A
Rheumatol Int; 2007 Mar; 27(5):425-34. PubMed ID: 17216477
[TBL] [Abstract][Full Text] [Related]
32. Fluoride for the treatment of postmenopausal osteoporotic fractures: a meta-analysis.
Haguenauer D; Welch V; Shea B; Tugwell P; Adachi JD; Wells G
Osteoporos Int; 2000; 11(9):727-38. PubMed ID: 11148800
[TBL] [Abstract][Full Text] [Related]
33. Monofluorophosphate increases lumbar bone density in osteopenic patients: a double-masked randomized study.
Sebert JL; Richard P; Mennecier I; Bisset JP; Loeb G
Osteoporos Int; 1995 Mar; 5(2):108-14. PubMed ID: 7599447
[TBL] [Abstract][Full Text] [Related]
34. Sustained-release sodium fluoride in the treatment of the elderly with established osteoporosis.
Rubin CD; Pak CY; Adams-Huet B; Genant HK; Li J; Rao DS
Arch Intern Med; 2001 Oct; 161(19):2325-33. PubMed ID: 11606148
[TBL] [Abstract][Full Text] [Related]
35. Reappraisal of Katsuragi calcium study, a prospective, double-blind, placebo-controlled study of the effect of active absorbable algal calcium (AAACa) on vertebral deformity and fracture.
Fujita T; Ohue M; Fujii Y; Miyauchi A; Takagi Y
J Bone Miner Metab; 2004; 22(1):32-8. PubMed ID: 14691684
[TBL] [Abstract][Full Text] [Related]
36. Relationships between bone mineral density and incident vertebral fracture risk with raloxifene therapy.
Sarkar S; Mitlak BH; Wong M; Stock JL; Black DM; Harper KD
J Bone Miner Res; 2002 Jan; 17(1):1-10. PubMed ID: 11771654
[TBL] [Abstract][Full Text] [Related]
37. Alendronate reduced vertebral fracture risk in postmenopausal Japanese women with osteoporosis: a 3-year follow-up study.
Kushida K; Shiraki M; Nakamura T; Kishimoto H; Morii H; Yamamoto K; Kaneda K; Fukunaga M; Inoue T; Nakashima M; Orimo H
J Bone Miner Metab; 2004; 22(5):462-8. PubMed ID: 15316867
[TBL] [Abstract][Full Text] [Related]
38. Effect of intermittent administration of 200 IU intranasal salmon calcitonin and low doses of 1alpha(OH) vitamin D3 on bone mineral density of the lumbar spine and hip region and biochemical bone markers in women with postmenopausal osteoporosis: a pilot study.
Kaskani E; Lyritis GP; Kosmidis C; Galanos A; Andypas G; Chorianopoulos K; Giagiosis A; Iliadou K; Karagianis A; Katsimichas K; Koskinas A; Matsouka K
Clin Rheumatol; 2005 Jun; 24(3):232-8. PubMed ID: 15647969
[TBL] [Abstract][Full Text] [Related]
39. Quantitative computed tomography of the lumbar spine, not dual x-ray absorptiometry, is an independent predictor of prevalent vertebral fractures in postmenopausal women with osteopenia receiving long-term glucocorticoid and hormone-replacement therapy.
Rehman Q; Lang T; Modin G; Lane NE
Arthritis Rheum; 2002 May; 46(5):1292-7. PubMed ID: 12115236
[TBL] [Abstract][Full Text] [Related]
40. Two-year efficacy and tolerability of risedronate once a week for the treatment of women with postmenopausal osteoporosis.
Harris ST; Watts NB; Li Z; Chines AA; Hanley DA; Brown JP
Curr Med Res Opin; 2004 May; 20(5):757-64. PubMed ID: 15140343
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
